Novo Nordisk, which has stumbled through a bit of a manufacturing hangover at a former Catalent production site it picked up a year ago, was hit with a warning letter from the FDA last month. The ...
When Novo Nordisk launched Wegovy, its pioneering weight-loss jab, in America in June 2021, it felt like it was “running into a dark tunnel”, recalls Maziar Mike Doustdar, who took over as the Danish ...
Novo Nordisk (NVO) appears undervalued relative to Big Pharma peers, especially given its superior long-term growth and profitability metrics outside of recent setbacks. NVO’s two-thirds market cap ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback